CMV status refers to whether your body has been exposed to cytomegalovirus, a common virus that infects more than 50% of adults by age 40 in the United States. It’s determined by a blood test that checks for antibodies against the virus. Your result will come back as either CMV-positive (you’ve been infected at some point) or CMV-negative (you haven’t). This distinction matters most during organ transplantation, pregnancy, blood transfusion, and any situation involving a weakened immune system.
How CMV Status Is Tested
The standard test looks for a specific type of antibody called IgG in your blood. A positive CMV IgG result means you were infected with the virus at some point in your life, though it doesn’t tell you when. Since the virus stays in your body permanently after infection, a positive result is a permanent status. For people 12 months and older, this test reliably reflects your own infection history rather than antibodies passed from your mother during pregnancy.
If your doctor needs to know whether an infection is recent or old, additional testing comes into play. A second antibody type called IgM can indicate a newer infection, but it isn’t definitive on its own because IgM can also appear during reactivation of an old infection. The most reliable way to confirm a recent first-time infection is either seroconversion (testing negative on one blood draw and positive on a follow-up) or finding IgM antibodies combined with low IgG avidity, a measure of how tightly your antibodies bind to the virus. Low avidity suggests your immune system is still learning to fight CMV, pointing to a recent infection.
What CMV Actually Does in Your Body
Most healthy people who catch CMV never realize it. When symptoms do appear, they tend to be mild: fever, sore throat, fatigue, and swollen glands. Occasionally it causes mononucleosis or liver inflammation. After the initial infection clears, the virus doesn’t leave. It settles into bone marrow cells called hematopoietic progenitor cells, where it establishes a lifelong latent infection. From there, latently infected immune cells called monocytes can carry the virus throughout the body.
The virus stays dormant unless something stirs it up. Reactivation is triggered by inflammation, infection with other pathogens, tissue injury, or anything that activates your body’s stress and damage-response pathways. In healthy people with functioning immune systems, reactivation is typically controlled before it causes problems. In people with weakened immune systems, reactivated CMV can cause serious illness affecting the eyes, lungs, liver, esophagus, stomach, and intestines.
Why CMV Status Matters for Transplants
This is where CMV status carries the highest stakes. Before an organ transplant, both the donor and recipient are tested, and results are recorded as a combination: D+/R+ means both have been exposed, D+/R- means the donor is positive but the recipient is negative, and so on. The riskiest combination is D+/R-, where a CMV-positive organ goes into a CMV-negative recipient. That recipient has no pre-existing immunity to the virus and is simultaneously taking immune-suppressing drugs to prevent organ rejection.
The numbers are striking. A large study of over 31,000 kidney transplant recipients with D+/R- mismatch found a 29% increased risk of death and a 17% increased risk of graft failure at one year compared to D+/R+ recipients. On average, a D+/R- recipient lost more than three months of post-transplant survival time. Primary CMV infection in these patients typically develops within the first three months after surgery. The risk was especially pronounced in patients aged 40 and older.
Beyond the direct infection, CMV acts as an immune system disruptor. It has been linked to acute organ rejection, chronic damage to the transplanted organ, coronary artery disease in heart transplant recipients, and a form of airway scarring called bronchiolitis obliterans in lung transplant recipients. These indirect effects mean CMV mismatch isn’t just about managing an infection; it influences long-term transplant outcomes. Some experts now advocate for matching CMV status when allocating donor organs, particularly for high-risk patients.
CMV Status in Pregnancy
For pregnant women, CMV status matters because the virus can cross the placenta and infect the developing baby, a condition called congenital CMV. The risk depends heavily on whether the mother is experiencing her first infection or a recurrence. A first-time (primary) infection during pregnancy transmits the virus to the fetus about 32% of the time, with rates ranging from 14% to 52%. A recurrent infection, either reactivation of an old infection or exposure to a different strain, transmits at a much lower rate of roughly 1.4%.
This is why knowing a woman’s CMV status before or early in pregnancy can be informative. A woman who tests CMV-negative knows she’s at risk for a primary infection if exposed, which carries the higher transmission rate. A woman who is already CMV-positive has some existing immunity that substantially reduces, though doesn’t eliminate, the risk to her baby. Congenital CMV can cause hearing loss, developmental delays, and other serious problems, making it the most common infectious cause of birth defects in the United States.
Newborn Screening
Several medical organizations, including the American Academy of Otolaryngology and the American Academy of Audiology, have recommended universal CMV screening for newborns. In practice, many states have adopted a targeted approach: testing babies who fail their newborn hearing screen, since hearing loss is one of the most common consequences of congenital CMV. These legislative mandates have largely been driven by advocacy from families affected by the condition. The American Academy of Pediatrics is still evaluating universal screening, which has left a gap that state-level legislation is filling unevenly.
CMV Status and Blood Transfusion
Blood banks test donations for CMV and label units accordingly. CMV-negative blood products are specifically indicated for immunocompromised patients and those who have received or are being prepared for a stem cell transplant (also called a hematopoietic stem cell transplant). For these patients, receiving CMV-positive blood could introduce a new infection their immune system can’t handle.
For other patients, a processing technique called leukoreduction, which filters out white blood cells that carry the virus, is widely used and has been proposed as an equally effective alternative to requiring CMV-negative donors. Since roughly half of all adults are CMV-positive, maintaining a large enough supply of CMV-negative blood is a constant logistical challenge for blood banks, making leukoreduction a practical workaround for lower-risk situations.
How Common CMV Infection Is
CMV is far more widespread than most people realize. In the U.S., about 30% of children are infected by age 5, and over half of adults are positive by 40. Rates among women of reproductive age vary widely by region: 25% to 81% in North America, 46% to 96% in Europe, and up to 95% in parts of Latin America. Among elderly populations, seroprevalence climbs above 90%. The virus spreads through saliva, urine, breast milk, sexual contact, and close physical contact, which is why young children in daycare settings are a common source of transmission to adults.
If you’ve been told your CMV status as part of a routine screening, a transplant evaluation, or prenatal care, the result itself isn’t a diagnosis of active disease. It’s a snapshot of your immune history with a very common virus, one that becomes clinically relevant mainly when immune function is compromised or when the risk of passing the virus to someone vulnerable is on the table.